Tumor-Associated Macrophages as Target for Antitumor Therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abdelraouf F, Smit E, Hasan B et al (2016) Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a “chemosensitive” relapse: a single-arm phase II study (EORTC-08061). Eur J Cancer 54:35–39
Ahn GO, Tseng D, Liao CH et al (2010) Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 107:8363–8368
Albeituni SH, Ding C, Liu M et al (2016) Yeast-derived particulate β-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer. J Immunol 196:2167–2180
Alderson KL, Luangrath M, Elsenheimer MM et al (2013) Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother 62:665–675
Allavena P, Signorelli M, Chieppa M et al (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65:2964–2971
Allavena P, Sica A, Solinas G et al (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66:1–9
Angevin E, Tabernero J, Elez E et al (2014) A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 20:2192–2204
Armstrong AJ, Halabi S, Healy P et al (2016) A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis 19:100–106
Banciu M, Metselaar JM, Schiffelers RM et al (2008) Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J Steroid Biochem Mol Biol 111:101–110
Beatty GL, Chiorean EG, Fishman MP et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612–1616
Beatty GL, Torigian DA, Chiorean EG et al (2013) A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19:6286–6295
Beider K, Bitner H, Leiba M et al (2014) Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 5:11283–11296
Biragyn A, Longo DL (2012) Neoplastic “Black Ops”: cancer’s subversive tactics in overcoming host defenses. Semin Cancer Biol 22:50–59
Bissell MJ, Hines WC (2011) Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17:320–329
Boimel PJ, Smirnova T, Zhou ZN et al (2012) Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res 14:R23
Brana I, Calles A, LoRusso PM et al (2015) Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol 10:111–123
Bruchard M, Mignot G, Derangère V et al (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19:57–64
Buhtoiarov IN, Lum HD, Berke G et al (2006) Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 176:309–318
Butowski N, Colman H, De Groot JF et al (2016) Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 18:557–564
Cabanillas ME, Habra MA (2016) Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47–55
Cabarcas SM, Mathews LA, Farrar WL (2011) The cancer stem cell niche–there goes the neighborhood? Int J Cancer 129:2315–2327
Cai X, Yin Y, Li N et al (2012) Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol 4:341–343
Chai ZT, Zhu XD, Ao JY et al (2015) microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. J Hematol Oncol 8:56
Chang LS, Leng CH, Yeh YC et al (2014) Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer 13:60
Chen R, Chen B (2015) Siltuximab (CNTO 328): a promising option for human malignancies. Drug Des Dev Ther 9:3455–3458
Cheng F, Wang HW, Cuenca A et al (2003) A critical role for Stat3 signaling in immune tolerance. Immunity 19:425–436
Choi MR, Stanton-Maxey KJ, Stanley JK et al (2007) A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 7:3759–3765
Chowdhury F, Johnson PW, Glennie MJ et al (2014) Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunol Res 2:229–240
Conde J, Bao C, Tan Y et al (2015) Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells. Adv Funct Mater 25:4183–4194
Connelly L, Barham W, Onishko HM et al (2011) NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model. Breast Cancer Res 13:R83
Coward J, Kulbe H, Chakravarty P et al (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17:6083–6096
D’Ignazio L, Bandarra D, Rocha S (2016) NF-κB and HIF crosstalk in immune responses. FEBS J 283:413–424
Dai Y, Qiao L, Chan KW et al (2009) Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. Cancer Res 69:4776–4783
De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23:277–286
Deng YR, Liu WB, Lian ZX et al (2016) Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget 7:38292–38305
Ding P, Wang W, Wang J et al (2014) Expression of tumor-associated macrophage in progression of human glioma. Cell Biochem Biophys 70:1625–1631
Ding L, Liang G, Yao Z et al (2015) Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget 6:36441–36455
Dirkx AE, Oude Egbrink MG, Wagstaff J et al (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80:1183–1196
Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219–230
Edwards JP, Emens LA (2010) The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages. Int Immunopharmacol 10:1220–1228
Escobar G, Gentner B, Naldini L et al (2014) Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression. Oncoimmunology 3:e28696
Fang WB, Yao M, Brummer G et al (2016) Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget 7:49349–49367
Fujiwara Y, Takeya M, Komohara Y (2014) A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int 2014:348539
Galmbacher K, Heisig M, Hotz C et al (2010) Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS One 5:e9572
Garaci E, Pica F, Serafino A et al (2012) Thymosin α1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci 1269:26–33
Georgoudaki AM, Prokopec KE, Boura VF et al (2016) Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 15:2000–2011
Germano G, Frapolli R, Simone M et al (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70:2235–2244
Germano G, Frapolli R, Belgiovine C et al (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23:249–262
Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604
Gordon EM, Sankhala KK, Chawla N et al (2016) Trabectedin for soft tissue sarcoma: current status and future perspectives. Adv Ther 33:1055–1071
Hagemann T, Lawrence T, McNeish I et al (2008) “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205:1261–1268
Hagemann T, Biswas SK, Lawrence T et al (2009) Regulation of macrophage function in tumors: the multifaceted role of NF-κB. Blood 113:3139–3146
Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9:216
Hiraoka K, Zenmyo M, Watari K et al (2008) Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 99:1595–1602
Hollmén M, Karaman S, Schwager S et al (2015) G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology 5:e1115177
Holtick U, Scheulen ME, von Bergwelt-Baildon MS et al (2011) Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 20:361–372
Huang Z, Zhang Z, Jiang Y et al (2012) Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release 158:286–292
Hughes R, Qian B-Z, Rowan C et al (2015) Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 75:3479–3491
Ikehara Y, Niwa T, Biao L et al (2006) A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 66:8740–8748
Jinushi M, Chiba S, Yoshiyama H et al (2011) Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 108:12425–12430
Johnson LD, Goubran HA, Kotb RR (2014) Histidine rich glycoprotein and cancer: a multi-faceted relationship. Anticancer Res 34:593–603
Johnson P, Challis R, Chowdhury F et al (2015) Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin Cancer Res 21:1321–1328
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759
Karkera J, Steiner H, Li W et al (2011) The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 71:1455–1465
Khan ANH, Kolomeyevskaya N, Singel KL et al (2015) Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget 6:11310–11326
Kim TS, Cavnar MJ, Cohen NA et al (2014) Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res 20:2350–2362
Kodumudi KN, Woan K, Gilvary DL et al (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16:4583–4594
Kono Y, Kawakami S, Higuchi Y et al (2014) In vitro evaluation of inhibitory effect of nuclear factor-kappaB activity by small interfering RNA on pro-tumor characteristics of M2-like macrophages. Biol Pharm Bull 37:137–144
Kosaka A, Ohkuri T, Okada H (2014) Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 63:847–857
Kubota Y, Takubo K, Shimizu T et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 206:1089–1102
Kumar V, Cheng P, Condamine T et al (2016) CD45 Phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44:303–315
Kurahara H, Takao S, Kuwahata T et al (2012) Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer. Ann Surg Oncol 19:2264–2271
Kushner BH, Cheung IY, Modak S et al (2014) Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res 20:1375–1382
Lang R (2005) Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology 210:63–76
Laoui D, Movahedi K, Van Overmeire E et al (2011) Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 55:861–867
Le Noci V, Tortoreto M, Gulino A et al (2015) Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. Oncoimmunology 4:e1040214
Le DT, Brockstedt DG, Nir-Paz R et al (2012) A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 18:858–868
Lee SJ, Kim MJ, Roberts TM (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2–15
Lewēn S, Zhou H, Hu H et al (2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother 57:507–515
Lim SY, Yuzhalin AE, Gordon-Weeks AN et al (2016) Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 7:28697–28710
Lin AY, Almeida JPM, Bear A et al (2013) Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One 8:e63550
Liu C, Sun C, Huang H et al (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63:2957–2964
Liu Z, Lv D, Liu S et al (2013) Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. PLoS One 8:e60190
Liu M, Luo F, Ding C et al (2015) Dectin-1 activation by a natural product β-glucan converts immunosuppressive macrophages into an M1-like phenotype. J Immunol 195:5055–5065
Lizotte PH, Baird JR, Stevens CA et al (2014) Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. Oncoimmunology 3:e28926
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Loberg RD, Ying C, Craig M et al (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67:9417–9424
Manthey CL, Johnson DL, Illig CR et al (2009) JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 8:3151–3161
Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231–237
Minardi D, Quaresima L, Santoni M et al (2015) Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature. Curr Urol Rep 16:3
Mitchem JB, Brennan DJ, Knolhoff BL et al (2013) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73:1128–1141
Moisan F, Francisco EB, Brozovic A et al (2014) Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol 8:1231–1239
Mota JM, Leite CA, Souza LE et al (2016) Post-sepsis state induces tumor-associated macrophage accumulation through CXCR4/CXCL12 and favors tumor progression in mice. Cancer Immunol Res 4:312–322
Moughon DL, He H, Schokrpur S et al (2015) Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res 75:4742–4752
Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618–631
Nagai T, Tanaka M, Tsuneyoshi Y et al (2009) Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 58:1577–1586
Neyen C, Plüddemann A, Mukhopadhyay S et al (2013) Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol 190:3798–3805
Ngambenjawong C, Cieslewicz M, Schellinger JG et al (2016) Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. J Control Release 224:103–111
Ngiow SF, Meeth KM, Stannard K et al (2015) Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF(V600E) melanoma. Oncoimmunology 5:e1089381
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49–61
Nywening TM, Wang-Gillam A, Sanford DE et al (2016) Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–662
O’Shannessy DJ, Somers EB, Wang LC et al (2015) Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. J Ovarian Res 8:29
Ortega RA, Barham WJ, Kumar B et al (2015) Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale 7:500–510
Ortega RA, Barham W, Sharman K et al (2016) Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions. Int J Nanomed 11:2163–2177
Paulus P, Stanley ER, Schäfer R et al (2006) Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res 66:4349–4356
Peng M, Huang B, Zhang Q et al (2014) Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. Cancer Lett 354:407–416
Piaggio F, Kondylis V, Pastorino F et al (2016) A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. J Control Release 223:165–177
Pienta KJ, Machiels J-P, Schrijvers D et al (2013) Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Investig New Drugs 31:760–768
Pitoia F, Jerkovich F (2016) Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Dev Ther 10:1119–1131
Popivanova BK, Kostadinova FI, Furuichi K et al (2009) Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69:7884–7892
Priceman SJ, Sung JL, Shaposhnik Z et al (2010) Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115:1461–1471
Puig-Kröger A, Sierra-Filardi E, Domínguez-Soto A et al (2009) Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 69:9395–9403
Pulaski HL, Spahlinger G, Silva IA et al (2009) Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 7:49
Pyonteck SM, Akkari L, Schuhmacher AJ et al (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264–1272
Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51
Remon J, Girard N, Mazieres J et al (2016) Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network. Lung Cancer 97:99–104
Resnier P, Montier T, Mathieu V et al (2013) A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 34:6429–6443
Ries CH, Cannarile MA, Hoves S et al (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25:846–859
Roberts AS, Campa MJ, Gottlin EB et al (2012) Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 118:571–578
Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177
Rolny C, Mazzone M, Tugues S et al (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19:31–44
Rossi J-F, Négrier S, James ND et al (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103:1154–1162
Sandhu SK, Papadopoulos K, Fong PC et al (2013) A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol 71:1041–1050
Segal NH, Gada P, Senzer N et al (2016) A phase II efficacy and safety, open-label, multicenter study of imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer. Clin Colorectal Cancer 15:222–227
Shen J, Putt KS, Visscher DW et al (2015) Assessment of folate receptor-β expression in human neoplastic tissues. Oncotarget 6:14700–14709
Shi Y, Felder MA, Sondel PM et al (2015) Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages. Mol Immunol 66:208–215
Shirota H, Klinman DM (2012) Effect of CpG ODN on monocytic myeloid derived suppressor cells. Oncoimmunology 1:780–782
Shirota Y, Shirota H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188:1592–1599
Shirota H, Tross D, Klinman DM (2015) CpG oligonucleotides as cancer vaccine adjuvants. Vaccines 3:390–407
Shrivastava P, Singh SM, Singh N (2004) Activation of tumor-associated macrophages by thymosin alpha 1. Int J Immunopathol Pharmacol 17:39–47
Shrivastava P, Singh SM, Singh N (2005) Antitumor activation of peritoneal macrophages by thymosin alpha-1. Cancer Invest 23:316–322
Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Investig 122:787–795
Sluijter M, van der Sluis TC, van der Velden PA et al (2014) Inhibition of CSF-1R supports T-cell mediated melanoma therapy. PLoS One 9:e104230
Smahel M, Duskova M, Polakova I et al (2014) Enhancement of DNA vaccine potency against legumain. J Immunother 37:293–303
Sośnicki S, Kapral M, Węglarz L (2016) Molecular targets of metformin antitumor action. Pharmacol Rep 68:918–925
Squadrito ML, Pucci F, Magri L et al (2012) miR-511-3p modulates genetic programs of tumor-associated macrophages. Cell Rep 1:141–154
Squadrito ML, Etzrodt M, De Palma M et al (2013) MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol 34:350–359
Stafford JH, Hirai T, Deng L et al (2016) Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol 18:797–806
Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology 2:e26968
Su MJ, Aldawsari H, Amiji M (2016) Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems. Sci Rep 6:30110
Tang X, Mo C, Wang Y et al (2013) Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 138:93–104
Tian J, Ma J, Ma K et al (2013) β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol 43:1220–1230
Van Acker HH, Anguille S, Willemen Y et al (2016) Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol Ther 158:24–40
Vonderheide RH, Glennie MJ (2013) Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19:1035–1043
Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876–883
Vonderheide RH, Bajor DL, Winograd R et al (2013a) CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62:949–954
Vonderheide RH, Burg JM, Mick R et al (2013b) Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2:e23033
Wang H, Shrestha TB, Basel MT et al (2012) Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages. Beilstein J Nanotechnol 3:444–455
Wang Z, Sun J, Feng Y et al (2016) Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. Tumor Biol 37:8515–8528
Wei Y, Schober A (2016) MicroRNA regulation of macrophages in human pathologies. Cell Mol Life Sci 73:3473–3495
Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422–439
Wu T, Dai Y, Wang W et al (2016) Macrophage targeting contributes to the inhibitory effects of embelin on colitis-associated cancer. Oncotarget 7:19548–19558
Xiang R, Luo Y, Niethammer AG et al (2008) Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 222:117–128
Xin H, Zhang C, Herrmann A et al (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69:2506–2513
Yang J, Hawkins OE, Barham W et al (2014) Myeloid IKKb promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Res 74:7274–7284
Zeisberger SM, Odermatt B, Marty C et al (2006) Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95:272–281
Zhan X, Jia L, Niu Y et al (2014) Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy. Biomaterials 35:10046–10057
Zhang W, Zhu XD, Sun HC et al (2010) Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16:3420–3430
Zhang QQ, Hu XW, Liu YL et al (2015) CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment. Sci Rep 5:15948